Skip to main content
. 2021 Apr 19;20:35. doi: 10.1186/s12944-021-01462-4

Table 1.

Characteristics of PD patients and healthy controls

Controls (n = 97) PD patients (n = 101) Z/T P
Sex (male, %) 52 (53.1%) 55 (56.1%) 0.185 0.667
Age (years) 67.5 (56.75 ~ 75) 68.5 (59 ~ 77) −0.587 0.557
Smoking (male-%) 5 (5.1%) 13 (13.3%) 3.915 0.048
Drinking (male-%) 1 (1%) 8 (8.2%) 0.035△
Hypertension (male-%) 32 (32.7%) 19 (19.4%) 4.479 0.034
Statin therapy 13 (13.3%) 27 (27.6%) 6.156 0.013
BMI (kg/m2) 24.69 (22.56 ~ 27.39) 23.02 (21.5 ~ 24.63) −3.812 < 0.001
WBCs (×109/L) 5.53 ± 1.16 5.65 ± 1.12 −0.713 0.477
Neutrophils (×109/L) 3.21 (2.62 ~ 3.88) 3.5 (2.94 ~ 4.37) −2.646 0.008
Lymphocytes (×109/L) 1.68 (1.32 ~ 2.11) 1.38 (1.15 ~ 1.79) −3.326 0.001
Monocytes (×109/L) 0.39 (0.32 ~ 0.44) 0.36 (0.31 ~ 0.48) −0.06 0.952
Hb (×109/L) 161.69 ± 20.26 157.87 ± 13.98 1.539 0.126
UA (μmol/L) 348.85 ± 77.51 303.09 ± 80.16 4.062 < 0.001
TC (mmol/L) 4.97 (4.27 ~ 5.5) 4.09 (3.72 ~ 4.8) −5.148 < 0.001
TG (mmol/L) 1.47 (1.15 ~ 2.24) 1.18 (0.87 ~ 1.66) −3.613 < 0.001
HDL-C (mmol/L) 1.32 ± 0.29 1.17 ± 0.29 3.488 0.001
LDL-C (mmol/L) 2.84 ± 0.82 2.45 ± 0.69 3.606 < 0.001
MHR (×109/mmol) 0.3 (0.23 ~ 0.38) 0.33 (0.25 ~ 0.43) −1.822 0.068
NHR (×109/mmol) 2.48 (1.74 ~ 3.34) 3.18 (2.33 ~ 4.04) −3.734 < 0.001
NLR (×109/mmol) 2.01 (1.52 ~ 2.54) 2.59 (2.02 ~ 3.18) −4.599 < 0.001
Parkinson’s drugs
 Compound levodopa (%) / 77 (78.57) / /
 DR agonist (%) / 29 (29.59) / /
 MAO-B inhibitors (%) / 28 (28.57) / /
 COMT inhibitors (%) / 8 (8.16) / /
 Anticholinergic drugs (%) / 8 (8.16) / /

Abbreviations: PD Parkinson’s disease, BMI body mass index, WBC white blood cell, UA uric acid, TC total cholesterol, Hb haemoglobin, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, MHR monocyte to HDL ratio, NHR neutrophil to HDL ratio, NLR neutrophil lymphocyte ratio

△: Fisher’s exact test